Overall, understanding the molecular cross-talk between AR signaling in CAFs and prostate cancer cells could pave the way for novel therapeutic approaches to combat drug resistance and metastatic disease in prostate cancer (Figure 2). The gene discussed is AR; the disease is prostate carcinoma.